All In Biotech

Drug Trial Radar · NCT03439124

Ceftobiprole in the Treatment of Pediatric Patients With Pneumonia

A Multicentre, Randomized, Investigator-blind, Active-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of Ceftobiprole Versus Intravenous Standard-of-care Cephalosporin Treatment With or Without Vancomycin in Pediatric Patients Aged From 3 Months to Less Than 18 Years With Hospital-acquired Pneumonia or Community-acquired Pneumonia Requiring Hospitalisation

Last checked: Nov 20, 2026Latest source record: May 12, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 138 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

138

Actual

Start

Nov 27, 2017

Primary completion

Mar 16, 2020

Study completion Mar 16, 2020

Sponsor

Lead sponsor
Basilea PharmaceuticaIndustry
Sponsor type
Industry
First posted
Feb 20, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 3 months, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This was a study of the safety and efficacy of ceftobiprole medocaril compared with intravenous (IV) standard-of-care cephalosporin treatment with or without vancomycin in pediatric patients with either hospital-acquired bacterial pneumonia (HAP) or community-acquired bacterial pneumonia (CAP) requiring hospitalization, and requiring intravenous (IV) antibiotic therapy.

Conditions

  • Community-acquired Pneumonia (CAP)
  • Hospital-acquired Pneumonia (HAP)

Interventions

  • ceftobiprole medocarilDrug

    Ceftobiprole medocaril was administered at age-adjusted doses (10, 15 or 20 mg/kg) and infusion durations (2 or 4 hours) every 8 hours. The maximum dose, regardless of body weight, was 500 mg ceftobiprole every 8 hours (maximum total daily dose of 1500 mg ceftobiprole). After a minimum of 3 days of IV treatment, patients with sufficient improvement in disease signs and symptoms could be switched to an age-appropriate oral antibiotic to complete a total minimum of 7 days and a total maximum of 14 days' antibiotic treatment.

  • IV standard-of-care cephalosporinDrug

    Ceftriaxone was administered at 50 to 80 mg/kg IV as a single daily dose, up to a maximum dose of 2 g/day. The actual dose of ceftriaxone within this dose range was determined by the blinded investigator prior to first study drug administration and was not modified during subsequent study days. After a minimum of 3 days of IV treatment, patients with sufficient improvement in disease signs and symptoms could be switched to an age-appropriate oral antibiotic to complete a total minimum of 7 days and a total maximum of 14 days' antibiotic treatment. At the discretion of the blinded investigator, patients received vancomycin at a dose of 10 to 15 mg/kg IV every 6 hours, up to a maximum dose of 2 g/day, in addition to the IV standard-of-care cephalosporin when MRSA was suspected or confirmed.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse EventsTime frame: Analysis of AEs assessed during the first 3 days of IV therapy and while on IV, a median of 7 days

Locations

19 sites in 4 countries. Site status is shown where the registry gives one.

  • University Multiprofile Hospital for Active Treatment "Dr. Georgi Stranski"

    Pleven, Bulgaria

  • University Multiprofile Hospital for Active Treatment "Sveti Georgi"

    Plovdiv, Bulgaria

  • Multiprofile Hospital for Active Treatment

    Rousse, Bulgaria

  • University Multiprofile Hospital for Active Treatment "Aleksandrovska"

    Sofia, Bulgaria

  • Amtel Hospital First Clinical LLC

    Tbilisi, Georgia

  • LTD High Technology Medical Center University Clinic

    Tbilisi, Georgia

  • JSC Evex Hospitals 1

    Tbilisi, Georgia

  • JSC Evex Hospitals 2

    Tbilisi, Georgia

  • Tbilisi State Medical University G. Zhvania Pediatric Academic Clinic

    Tbilisi, Georgia

  • Ltd Tbilisi Pediatric Private Clinic

    Tbilisi, Georgia

  • Principal SMO Ltd.

    Baja, Hungary

  • Semmelweis University

    Budapest, Hungary

  • Central Hospital of Southern Pest National Institute of Hematology and Infectious Diseases

    Budapest, Hungary

  • Bekes County Central Hospital

    Gyula, Hungary

  • Kanizsai Dorottya Hospital

    Nagykanizsa, Hungary

  • Fejer County St. Gyorgy University Teaching Hospital

    Székesfehérvár, Hungary

  • Torokbalint Pulmonology Institute

    Törökbálint, Hungary

  • Alessandrescu-Rusescu National Institute for Mother and Child Health

    Bucharest, Romania

  • Sf. Maria" Children's Emergency Clinical Hospital

    Iași, Romania

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.